FDA issues draft guidance on patient-focused drug development

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA issued a draft guidance, “Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments.”

This guidance is the third in a series of documents intended to facilitate the advancement and use of systematic approaches to collect and use robust and meaningful patient and caregiver input that can more consistently inform medical product development and regulatory decision-making. 

When final, this guidance will represent the current thinking of FDA’s Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, and Center for Devices and Radiological Health on this topic.

The purpose of this guidance is to help sponsors identify or develop fit-for-purpose COA measures of patients’ health that are appropriate for use in a medical product development program.

For information on the draft guidance and how to submit comments, please see the Federal Register Notice. 

In addition, FDA issued two final guidances for bladder cancer and renal cell carcinoma.

Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
FDA approved penpulimab-kcqx with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma. FDA also approved penpulimab-kcqx as a single agent for adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login